BridgeBio Oncology Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 12, 2026

BBOT$2.04-6.0%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned thereunto duly authorized.

	BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.
Date: May 12, 2026	By:	/s/ Pedro J. Beltran
		Pedro J. Beltran, Ph.D.
		Chief Executive Officer
Date: May 12, 2026	By:	/s/ Idan Elmelech
		Idan Elmelech
		Chief Operating and Principal Financial Officer

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.